Investing.com - Puma Biotech (NASDAQ: PBYI) reported first quarter EPS of $-0.070, $0.12 worse than the analyst estimate of $0.050. Revenue for the quarter came in at $53.7M versus the consensus estimate of $57.06M.
Guidance
Puma Biotech sees Q1 2023 revenue of $43.000M-$46.000M versus the analyst consensus of $51.000M.
Puma Biotech sees FY 2023 revenue of $205.000M-$210.000M versus the analyst consensus of $227.400M.
Puma Biotech's stock price closed at $3.980. It is down -10.560% in the last 3 months and up 70.820% in the last 12 months.
Puma Biotech saw 0 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See Puma Biotech's stock price’s past reactions to earnings here.
According to InvestingPro, Puma Biotech's Financial Health score is "good performance".
Check out Puma Biotech's recent earnings performance, and Puma Biotech's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar